Study to evaluate BioBridge™ use in surgical management of secondary lymphedema
September 01, 2016
UNION CITY, Calif.–(BUSINESS WIRE)–Fibralign Corporation announced that Stanford University has started enrollment in its investigator-led clinical study to evaluate the efficacy of a new surgical device for treating secondary lymphedema.
“We continue to be impressed and encouraged by the progress that Fibralign has been making toward providing new treatments for lymphedema since the NLN first recognized the Fibralign with its 2014 Best New Innovator Award”
The trial will evaluate the effectiveness of Fibralign’s BioBridge™ Collagen Matrix in supporting and guiding lymphatic repair in patients with acquired lymphedema of upper and lower extremities. Stanford plans to enroll at least 36 patients into the study, which will utilize BioBridge as an adjunctive interventional device for vascularized lymph node transfer (VLNT) surgery. VLNT is an increasingly practiced micro-surgical procedure for patients with lymphedema, in which an auxiliary lymph node is autologously transplanted as a tissue flap to the treatment area.